A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer.



Status:Recruiting
Conditions:Breast Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 127
Updated:3/29/2019
Start Date:December 21, 2018
End Date:December 31, 2020
Contact:AstraZeneca Clinical Study Information Center
Email:information.center@astrazeneca.com
Phone:1-877-240-9479

Use our guide to learn which trials are right for you!

A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination With Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer.

This study is designed to determine the efficacy and safety of durvalumab in combination with
paclitaxel and multiple novel oncology therapies and durvalumab with paclitaxel alone for the
treatment of first-line metastatic triple negative breast cancer.

This is a Phase IB/II, 2-stage, open-label, multicenter study to determine the efficacy and
safety of durvalumab + paclitaxel + novel oncology therapies (i.e. therapies designed for
immune modulation) and durvalumab + paclitaxel alone as first-line treatment in patients with
metastatic triple negative breast cancer (TNBC). The study is designed to concurrently
evaluate potential novel triplet combinations with clinical promise using a 2-stage approach.
Part 1 is a Phase IB study of safety and initial efficacy, and Part 2 is a Phase II study.
The triplet treatment regimens evaluated in Part 2 will depend on the evaluation of safety
and efficacy outcomes in Part 1.

Inclusion criteria

1. Female

2. At least 18 years of age at the time of screening

3. Patient must have locally confirmed TNBC

4. No prior treatment for metastatic (Stage IV) TNBC

5. Patient must have at least 1 lesion, not previously irradiated, that can be accurately
measured

6. WHO/ECOG status at 0 or 1 at enrollment

Exclusion criteria

1. History of venous thromboembolism in the past 3 months

2. Diagnosis of diabetes mellitus Type I or diabetes mellitus Type II requiring insulin
treatment

3. History of allogeneic organ transplantation

4. Active or prior documented autoimmune or inflammatory disorders

5. Active infection including tuberculosis, hepatitis B (known positive HBV surface
antigen [HBsAg] result), hepatitis C virus (HCV), or human immunodeficiency virus
(positive HIV 1/2 antibodies)

6. Untreated CNS metastases

7. Known allergy or hypersensitivity to any of the study drugs or any of the study drug
excipients

8. Any concurrent chemotherapy, IP, or biologic therapy for cancer treatment

9. Female patients who are pregnant or breastfeeding
We found this trial at
11
sites
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Goodyear, AZ
Click here to add this to my saved trials
?
mi
from
Kelowna,
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Newnan, GA
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Saint Petersburg, Florida 33713
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
?
mi
from
Zion, IL
Click here to add this to my saved trials